DEVELOPMENT AND REGISTRATION OF A COMBINED DRUG FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) PHOSPHAZIDE AND LAMIVUDINE

DEVELOPMENT AND REGISTRATION OF A COMBINED DRUG FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) PHOSPHAZIDE AND LAMIVUDINE

The article discusses the development process of a combined medicinal product Phosphaladin® intended for the treatment of HIV infection, based on phosphazide and lamivudine. A brief review of epidemiological situation on HIV infection taking into account the import substitution policy in the pharmac...

Full description

Saved in:
Bibliographic Details
Main Authors: A. F. Khohlov, B. V. Brovchenko, A. A. Smirnov
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2019-01-01
Series:Разработка и регистрация лекарственных средств
Subjects:
phosphazide
lamivudine
combined medicine
therapy of hiv infection
pharmaceutical development
Online Access:https://www.pharmjournal.ru/jour/article/view/221
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The article discusses the development process of a combined medicinal product Phosphaladin® intended for the treatment of HIV infection, based on phosphazide and lamivudine. A brief review of epidemiological situation on HIV infection taking into account the import substitution policy in the pharmaceutical industry, as well as the problem of providing HIV-infected patients require therapy. Considers the issues of pharmaceutical development combined drug and preparation of preclinical and clinical units of the registration dossier.
ISSN:2305-2066
2658-5049

Similar Items